Drive care: System for monitoring driver’s concentration and consciousness using consumer grade electonnencephalogram (EEG) headset 護駕: 利用消費級可裝載腦波監測儀實現實時監控駕駛者專注度系統

As people increasingly drive cars for both work and personal purposes, the dangers posed by drug driving, drink driving or sleep-deprived driving are growing threats to society. Highly dangerous driving behaviour and numerous traffic accidents occur because drivers are insufficiently conscious or inadequately focused while driving... 不論是為了工作還是個人需要，不少人都愛自行駕車，但藥後駕駛、醉酒駕駛、或駕駛前睡眠不足，往往容易對巿民的安全構成威脅。司機無法保持清醒或專注地駕駛而導致高危駕駛行為或交通意外，屢見不鮮... Award: Silver奬項: 銀

Lean manufacturing and environmental performance – exploring the impact and relationship

The relationship between Lean Manufacturing and Environmental Performance has attracted much debate but at the same time lack of empirical evidence leaves haphazard opinions on this matter. The objective of this paper is therefore to pro-vide some insight into the impact of Lean Manufacturing on Environmental Per-formance and the existing relationship of these two concepts. Four semi-structured interviews with industrial and academic experts provided a solid ground to suggest that the relationship does exist, despite the fact that these two concepts were developed independently from each other. Being the exploratory nature of this study and its purpose to ignite further research, it does not employ a quantitative approach. The results of this study can help managers to better un-derstand and concurrently tackle both the economic and environmental challenges faced by their organizations.N/

The efficacy and safety of Yupingfeng Powder with variation in the treatment of allergic rhinitis: Study protocol for a randomized, double-blind, placebo-controlled trial

Background: Allergic rhinitis (AR) is an upper airways chronic inflammatory disease mediated by IgE, which affects 10%–20% of the population. The mainstay for allergic rhinitis nowadays include steroids and antihistamines, but their effects are less than ideal. Many patients therefore seek Chinese medicine for treatment and Yupingfeng Powder is one of the most common formulae prescribed. In this study, we aim to investigate the efficacy and safety of Yupingfeng Powder with variation for the treatment of allergic rhinitis.Study design: This is a double-blind, randomized, placebo-controlled trial. A 2-week screening period will be implemented, and then eligible subjects with allergic rhinitis will receive interventions of either “Yupingfeng Powder with variation” granules or placebo granules for 8 weeks, followed by post treatment visits at weeks 12 and 16. The change in the Total Nasal Symptom Score (TNSS) will be used as the primary outcome.Discussion: This trail will evaluate the efficacy and safety of Yupingfeng Powder in treating allergic rhinitis. The study may provide the solid evidence of Yupingfeng Powder with variation can produce better clinical efficacy than the placebo granules.Trial registration:ClinicalTrials.gov, identifier NCT04976023

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

Scalability of Quasi-Hysteretic FSM-Based Digitally Controlled Single-Inductor Dual-String Buck LED Driver to Multiple Strings

There has been growing interest in single-inductor multiple-output (SIMO) dc-dc converters due to its reduced cost and smaller form factor in comparison with using multiple single-output converters. An application for such a SIMO-based switching converter is to drive multiple LED strings in a multichannel LED display. This paper proposes a quasi-hysteretic finite-state-machine-based digitally controlled single-inductor dual-output buck switching LED driver operating in discontinuous conduction mode (DCM) and extends it to drive multiple outputs. Based on the time-multiplexing control scheme in DCM, a theoretical upper limit of the total number of outputs in a SIMO buck switching LED driver for various backlight LED current values can be derived analytically. The advantages of the proposed SIMO LED driver include reducing the controller design complexity by eliminating loop compensation, driving more LED strings without limited by the maximum LED current rating, performing digital dimming with no additional switches required, and optimization of local bus voltage to compensate for variability of LED forward voltage V-F in each individual LED string with smaller power loss. Loosely binned LEDs with larger V-F variation can, therefore, be used for reduced LED costs

Adaptive high-bandwidth digitally controlled buck converter with improved line and load transient response

Digitally controlled switching converter suffers from bandwidth limitation because of the additional phase delay in the digital feedback control loop. To overcome the bandwidth limitation without using a high sampling rate, this study presents an adaptive third-order digital controller for regulating a voltage-mode buck converter with a modest 2x oversampling ratio. The phase lag because of the analogue-to-digital converter (ADC) conversion time delay is virtually compensated by providing an early estimation of the error voltage for the next sampling time instant, enabling a higher unity-gain bandwidth without compromising stability. An additional pair of low-frequency pole and zero in the third-order controller increases the low-frequency gain, resulting in faster settling time and smaller output voltage deviation during line transient. Both simulation and experimental results demonstrate that the proposed adaptive third-order controller reduces the settling time by 50% in response to a 1 V line transient and 30% in response to a 600 mA load transient, compared to the baseline static second-order controller. The fastest settling time is measured to be about 11.70 mu s, surpassing the transient performance of conventional digital controllers and approaching that of the state-of-the-art analogue-based controllers

The Translation of Mobile-Exoneuromusculoskeleton-Assisted Wrist–Hand Poststroke Telerehabilitation from Laboratory to Clinical Service

Rehabilitation robots are helpful in poststroke telerehabilitation; however, their feasibility and rehabilitation effectiveness in clinical settings have not been sufficiently investigated. A non-randomized controlled trial was conducted to investigate the feasibility of translating a telerehabilitation program assisted by a mobile wrist/hand exoneuromusculoskeleton (WH-ENMS) into routine clinical services and to compare the rehabilitative effects achieved in the hospital-service-based group (n = 12, clinic group) with the laboratory-research-based group (n = 12, lab group). Both groups showed significant improvements (p ≤ 0.05) in clinical assessments of behavioral motor functions and in muscular coordination and kinematic evaluations after the training and at the 3-month follow-up, with the lab group demonstrating better motor gains than the clinic group (p ≤ 0.05). The results indicated that the WH-ENMS-assisted tele-program was feasible and effective for upper limb rehabilitation when integrated into routine practice, and the quality of patient–operator interactions physically and remotely affected the rehabilitative outcomes

Gender Variance and PsychologicalWell-being in Chinese Community Children

Childhood gender variance (GV) and its association with psychological well-being have garnered increasing interest recently but little is known about children from the community and non-Western samples. Therefore, we examined GV and its associations with psychological well-being in a Chinese community sample where study of childhood GV is extremely rare. Parents of 461 Chinese children aged 4–12 years (243 birthassigned males) provided information on GV using the Gender Identity Questionnaire for Children (GIQC) and on psychological well-being. Children assigned female at birth (girls) were more gender-variant than children assigned male at birth (boys). In boys, higher GV correlated with lower happiness, lower selfworth, more behavior problems, and poorer peer relations. In boys, controlling for demographic covariates and adding peer relations as an independent variable, poorer peer relations also independently associated with lower happiness, lower self-worth, and more problem behaviors, and GV still associated with lower happiness and self-worth. In girls, GV minimally associated with psychological well-being but poorer peer relations associated with lower happiness, lower self-worth, and more problem behaviors. Peer relations did not moderate any effect of GVon psychological well-being. The GIQC demonstrated potential as a measurement tool outsideWestern contexts. Chinese boys who exhibit GV appear to face similar psychological well-being challenges as theirWestern counterparts. However, factors that moderate the association between GV and psychological well-being have yet to be identified in this population

Long-term effects of mobile exoneuromusculoskeleton (ENMS)-assisted self-help telerehabilitation after stroke

Investigation on long-term effects of robot-assisted poststroke rehabilitation is challenging because of the difficulties in administration and follow-up of individuals throughout the process. A mobile hybrid neuromuscular electrical stimulation (NMES)-robot, i.e., exoneuromusculoskeleton (ENSM) was adopted for a single-group trial to investigate the long-term effects of the robot-assisted self-help telerehabilitation on upper limb motor function after stroke. Twenty-two patients with chronic stroke were recruited to attend a 20-session telerehabilitation program assisted by the wrist/hand module of the ENMS (WH-ENMS). Participants were evaluated before, after, as well as at 3 months and 6 months after the training. The primary outcome measure was the Fugl-Meyer Assessment-Upper Extremity (FMA-UE), supplemented by secondary outcome measures of the FMA-UE of the shoulder and elbow (FMA shoulder/elbow), the FMA-UE of the wrist and hand (FMA wrist/hand), the Modified Ashworth Scale (MAS), the Action Research Arm Test (ARAT), the Wolf Motor Function Test (WMFT), the Functional Independence Measure (FIM), as well as electromyography (EMG) and kinematic measurements. Twenty participants completed the telerehabilitation program, with 19 returning for a 3-month follow-up, and 18 for a 6-month follow-up. Significantly improved clinical scores were observed after the training (p ≤ 0.05). These improvements were maintained after 6 months in the FMA-UE, FMA shoulder/elbow, MAS at the wrist flexor, WMFT score, WMFT time, and FIM (p ≤ 0.05). The maintained improvements in motor function were attributed to reduced muscular compensation, as indicated by EMG and kinematic parameters. The WH-ENMS-assisted self-help telerehabilitation could achieve long-lasting rehabilitative effects in chronic stroke